Tab Application Banner
  • Users Online: 374
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
CASE BASED REVIEW
Year : 2022  |  Volume : 17  |  Issue : 3  |  Page : 300-305

Monoclonal antibodies to treat COVID-19 in rheumatoid arthritis: A case report and a clinical appraisal of selected drug trials


Centre for Rheumatic Diseases, Pune, Maharashtra, India

Correspondence Address:
Dr. Arvind Chopra
Centre for Rheumatic Diseases, Hermes Elegance, 1988 Convent Street, Camp, Pune, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/injr.injr_5_22

Rights and Permissions

The current report describes successful treatment of a rapidly progressive severe breakthrough COVID-19 in a female physician, a known case of rheumatoid arthritis (RA). She received monoclonal antibody (Mab) combination cocktail (Casirivimab™ plus Imdevimab™) infusion on day 4 after the onset of symptoms. RA was in prolonged remission with tofacitinib. She had completed vaccination 6 weeks earlier and worked in a COVID hospital. Post infusion, there was substantial improvement, and she was discharged after 3 days. However, she required intermittent domiciliary oxygen for a fortnight. Fatigue and ageusia persisted for 5 weeks. Several Mabs were recently approved for emergency use in mild-to-moderate ambulant COVID-19 patients. Controlled drug trials confirmed excellent efficacy and safety. Selected data on clinical relevance and limitations are currently described. RA is susceptible to COVID-19, and some vaccines may be less effective. Intervention with Mabs ought to be judicious and timely.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed428    
    Printed12    
    Emailed0    
    PDF Downloaded24    
    Comments [Add]    

Recommend this journal